$GEVA Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in SYNAGEVA BIOPHARMA CORP.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in SYNAGEVA BIOPHARMA CORP. Get notifications about new insider transactions in SYNAGEVA BIOPHARMA CORP for free.
Page: < prev 1 ... 2 3 4 5 6 7 8 9 ... 9 next >
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Jun 29 2012 | GEVA | SYNAGEVA BIOPHARMA ... | Grinstead Eric | SVP, Commercial Ope ... | Option Exercise | A | 40.74 | 43,000 | 1,751,820 | 43,000 | |
| Jun 29 2012 | GEVA | SYNAGEVA BIOPHARMA ... | BAKER FELIX | Director | Option Exercise | A | 40.74 | 7,500 | 305,550 | 7,500 | |
| Jun 29 2012 | GEVA | SYNAGEVA BIOPHARMA ... | Biggar Stephen R | Director | Option Exercise | A | 40.74 | 7,500 | 305,550 | 7,500 | |
| Jun 28 2012 | GEVA | SYNAGEVA BIOPHARMA ... | AKKARAJU SRINIVAS | Sell | S | 39.70 | 313,451 | 12,444,005 | 1,026,832 | 1.3 M to 1 M (-23.39 %) | |
| Jun 28 2012 | GEVA | SYNAGEVA BIOPHARMA ... | AKKARAJU SRINIVAS | Sell | S | 40.16 | 28,827 | 1,157,661 | 1,340,283 | 1.4 M to 1.3 M (-2.11 %) | |
| Jun 05 2012 | GEVA | SYNAGEVA BIOPHARMA ... | Heberlig Chris | Vice President, Fin ... | Option Exercise | M | 0.95 | 1,000 | 950 | 6,877 | |
| Jun 05 2012 | GEVA | SYNAGEVA BIOPHARMA ... | Heberlig Chris | Vice President, Fin ... | Sell | S | 36.44 | 200 | 7,287 | 0 | 200 to 0 (-100.00 %) |
| Jun 05 2012 | GEVA | SYNAGEVA BIOPHARMA ... | Heberlig Chris | Vice President, Fin ... | Sell | S | 35.56 | 800 | 28,446 | 200 | 1,000 to 200 (-80.00 %) |
| Jun 05 2012 | GEVA | SYNAGEVA BIOPHARMA ... | Heberlig Chris | Vice President, Fin ... | Buy | M | 0.95 | 1,000 | 950 | 1,000 | 0 to 1,000 |
| Jun 05 2012 | GEVA | SYNAGEVA BIOPHARMA ... | Patel Sanj K | President & CEO | Option Exercise | M | 0.95 | 20,866 | 19,823 | 305,304 | |
| Jun 05 2012 | GEVA | SYNAGEVA BIOPHARMA ... | Patel Sanj K | President & CEO | Option Exercise | M | 0.95 | 9,234 | 8,772 | 107,986 | |
| Jun 05 2012 | GEVA | SYNAGEVA BIOPHARMA ... | Patel Sanj K | President & CEO | Option Exercise | M | 0.95 | 19,900 | 18,905 | 326,170 | |
| Jun 05 2012 | GEVA | SYNAGEVA BIOPHARMA ... | Patel Sanj K | President & CEO | Sell | S | 34.69 | 20,866 | 723,785 | 1,031 | 21.9 K to 1 K (-95.29 %) |
| Jun 05 2012 | GEVA | SYNAGEVA BIOPHARMA ... | Patel Sanj K | President & CEO | Buy | M | 0.95 | 20,866 | 19,823 | 21,897 | 1 K to 21.9 K (+2,023.86 %) |
| Jun 05 2012 | GEVA | SYNAGEVA BIOPHARMA ... | Patel Sanj K | President & CEO | Sell | S | 35.96 | 9,234 | 332,087 | 1,031 | 10.3 K to 1 K (-89.96 %) |
| Jun 05 2012 | GEVA | SYNAGEVA BIOPHARMA ... | Patel Sanj K | President & CEO | Sell | S | 35.70 | 19,900 | 710,446 | 10,265 | 30.2 K to 10.3 K (-65.97 %) |
| Jun 05 2012 | GEVA | SYNAGEVA BIOPHARMA ... | Patel Sanj K | President & CEO | Buy | M | 0.95 | 9,234 | 8,772 | 30,165 | 20.9 K to 30.2 K (+44.12 %) |
| Jun 05 2012 | GEVA | SYNAGEVA BIOPHARMA ... | Patel Sanj K | President & CEO | Buy | M | 0.95 | 19,900 | 18,905 | 20,931 | 1 K to 20.9 K (+1,930.16 %) |
| Jun 27 2012 | GEVA | SYNAGEVA BIOPHARMA ... | Quinn Anthony | SVP, Chief Medical ... | Sell | S | 40.65 | 26,000 | 1,056,874 | 20,035 | 46 K to 20 K (-56.48 %) |
| May 18 2012 | GEVA | SYNAGEVA BIOPHARMA ... | BOESS CARSTEN | SVP, Chief Financia ... | Option Exercise | M | 1.70 | 39,709 | 67,505 | 119,131 | |
| May 18 2012 | GEVA | SYNAGEVA BIOPHARMA ... | BOESS CARSTEN | SVP, Chief Financia ... | Sell | S | 38.82 | 11,572 | 449,225 | 0 | 11.6 K to 0 (-100.00 %) |
| May 18 2012 | GEVA | SYNAGEVA BIOPHARMA ... | BOESS CARSTEN | SVP, Chief Financia ... | Sell | S | 38.16 | 28,137 | 1,073,708 | 11,572 | 39.7 K to 11.6 K (-70.86 %) |
| May 18 2012 | GEVA | SYNAGEVA BIOPHARMA ... | BOESS CARSTEN | SVP, Chief Financia ... | Buy | M | 1.70 | 39,709 | 67,505 | 39,709 | 0 to 39.7 K |
| Apr 23 2012 | GEVA | SYNAGEVA BIOPHARMA ... | TISCH DANIEL R | 10% Owner | Sell | S | 40.10 | 3,000 | 120,300 | 44,750 | 47.8 K to 44.8 K (-6.28 %) |
| Apr 23 2012 | GEVA | SYNAGEVA BIOPHARMA ... | TISCH DANIEL R | 10% Owner | Sell | S | 39.66 | 10,000 | 396,600 | 47,750 | 57.8 K to 47.8 K (-17.32 %) |
| Mar 27 2012 | GEVA | SYNAGEVA BIOPHARMA ... | Patel Sanj K | President & CEO | Option Exercise | M | 0.95 | 50,000 | 47,500 | 346,070 | |
| Mar 27 2012 | GEVA | SYNAGEVA BIOPHARMA ... | Patel Sanj K | President & CEO | Sell | S | 33.53 | 50,000 | 1,676,410 | 1,031 | 51 K to 1 K (-97.98 %) |
| Mar 27 2012 | GEVA | SYNAGEVA BIOPHARMA ... | Patel Sanj K | President & CEO | Buy | M | 0.95 | 50,000 | 47,500 | 51,031 | 1 K to 51 K (+4,849.66 %) |
| Mar 21 2012 | GEVA | SYNAGEVA BIOPHARMA ... | AKKARAJU SRINIVAS | Director | Sell | S | 32.55 | 342,278 | 11,141,149 | 1,369,110 | 1.7 M to 1.4 M (-20.00 %) |
| Mar 09 2012 | GEVA | SYNAGEVA BIOPHARMA ... | TISCH DANIEL R | 10% Owner | Sell | S | 39.19 | 1,512 | 59,255 | 57,750 | 59.3 K to 57.8 K (-2.55 %) |
| Mar 09 2012 | GEVA | SYNAGEVA BIOPHARMA ... | TISCH DANIEL R | 10% Owner | Sell | S | 39.19 | 3,488 | 136,695 | 167,912 | 171.4 K to 167.9 K (-2.04 %) |
| Mar 09 2012 | GEVA | SYNAGEVA BIOPHARMA ... | TISCH DANIEL R | 10% Owner | Sell | S | 38.90 | 2,118 | 82,390 | 171,400 | 173.5 K to 171.4 K (-1.22 %) |
| Mar 09 2012 | GEVA | SYNAGEVA BIOPHARMA ... | TISCH DANIEL R | 10% Owner | Sell | S | 38.90 | 942 | 36,644 | 173,518 | 174.5 K to 173.5 K (-0.54 %) |
| Mar 09 2012 | GEVA | SYNAGEVA BIOPHARMA ... | TISCH DANIEL R | 10% Owner | Sell | S | 38.50 | 9,190 | 353,815 | 174,460 | 183.7 K to 174.5 K (-5.00 %) |
| Mar 09 2012 | GEVA | SYNAGEVA BIOPHARMA ... | TISCH DANIEL R | 10% Owner | Sell | S | 38.01 | 15,750 | 598,658 | 183,650 | 199.4 K to 183.7 K (-7.90 %) |
| Mar 09 2012 | GEVA | SYNAGEVA BIOPHARMA ... | TISCH DANIEL R | 10% Owner | Sell | S | 37.34 | 24,481 | 914,121 | 199,400 | 223.9 K to 199.4 K (-10.93 %) |
| Mar 09 2012 | GEVA | SYNAGEVA BIOPHARMA ... | TISCH DANIEL R | 10% Owner | Sell | S | 36.20 | 61,262 | 2,217,684 | 235,557 | 296.8 K to 235.6 K (-20.64 %) |
| Mar 09 2012 | GEVA | SYNAGEVA BIOPHARMA ... | TISCH DANIEL R | 10% Owner | Sell | S | 35.70 | 582 | 20,777 | 296,819 | 297.4 K to 296.8 K (-0.20 %) |
| Mar 09 2012 | GEVA | SYNAGEVA BIOPHARMA ... | TISCH DANIEL R | 10% Owner | Sell | S | 35.50 | 884 | 31,382 | 297,401 | 298.3 K to 297.4 K (-0.30 %) |
| Mar 09 2012 | GEVA | SYNAGEVA BIOPHARMA ... | TISCH DANIEL R | 10% Owner | Sell | S | 35.62 | 5,716 | 203,604 | 298,285 | 304 K to 298.3 K (-1.88 %) |
| Mar 09 2012 | GEVA | SYNAGEVA BIOPHARMA ... | TISCH DANIEL R | 10% Owner | Sell | S | 35.50 | 100 | 3,550 | 304,001 | 304.1 K to 304 K (-0.03 %) |
| Mar 09 2012 | GEVA | SYNAGEVA BIOPHARMA ... | TISCH DANIEL R | 10% Owner | Sell | S | 35.50 | 9,975 | 354,113 | 304,101 | 314.1 K to 304.1 K (-3.18 %) |
| Feb 29 2012 | GEVA | SYNAGEVA BIOPHARMA ... | Heberlig Chris | Vice President, Fin ... | Option Exercise | M | 0.95 | 4,500 | 4,275 | 7,877 | |
| Feb 29 2012 | GEVA | SYNAGEVA BIOPHARMA ... | Heberlig Chris | Vice President, Fin ... | Sell | S | 36.88 | 4,500 | 165,960 | 0 | 4.5 K to 0 (-100.00 %) |
| Feb 29 2012 | GEVA | SYNAGEVA BIOPHARMA ... | Heberlig Chris | Vice President, Fin ... | Buy | M | 0.95 | 4,500 | 4,275 | 4,500 | 0 to 4.5 K |
| Jan 11 2012 | GEVA | SYNAGEVA BIOPHARMA ... | TISCH THOMAS J | 10% Owner | Buy | P | 25.18 | 1,200,000 | 30,216,000 | 341,935 | -858,065 to 341.9 K (-139.85 %) |
| Jan 09 2012 | GEVA | SYNAGEVA BIOPHARMA ... | Baker Brothers Life Sciences C ... | Director | Grant | A | 25.18 | 1,077,225 | 27,124,526 | 5,077,676 | 4 M to 5.1 M (+26.93 %) |
| Jan 09 2012 | GEVA | SYNAGEVA BIOPHARMA ... | 14159 capital (GP), LLC | Director | Grant | A | 25.18 | 29,089 | 732,461 | 135,739 | 106.7 K to 135.7 K (+27.28 %) |
| Jan 09 2012 | GEVA | SYNAGEVA BIOPHARMA ... | Baker Biotech Capital (GP), LL ... | Director | Grant | A | 25.18 | 187,576 | 4,723,164 | 1,736,065 | 1.5 M to 1.7 M (+12.11 %) |
| Dec 22 2011 | GEVA | SYNAGEVA BIOPHARMA ... | DAVIS STEPHEN | Director | Option Exercise | A | 23.00 | 15,000 | 345,000 | 15,000 | |
| Dec 22 2011 | GEVA | SYNAGEVA BIOPHARMA ... | Patel Sanj K | Director and Presid ... | Option Exercise | A | 23.00 | 167,500 | 3,852,500 | 167,500 | |
| Dec 22 2011 | GEVA | SYNAGEVA BIOPHARMA ... | BOESS CARSTEN | CFO | Option Exercise | A | 23.00 | 25,000 | 575,000 | 25,000 | |
| Dec 22 2011 | GEVA | SYNAGEVA BIOPHARMA ... | Grinstead Eric | SVP, Commercial Ope ... | Option Exercise | A | 23.00 | 40,000 | 920,000 | 40,000 | |
| Dec 22 2011 | GEVA | SYNAGEVA BIOPHARMA ... | Quinn Anthony | SVP, Chief Medical ... | Option Exercise | A | 23.00 | 50,000 | 1,150,000 | 50,000 | |
| Dec 22 2011 | GEVA | SYNAGEVA BIOPHARMA ... | Quart Barry D | Director | Option Exercise | A | 23.00 | 15,000 | 345,000 | 15,000 | |
| Dec 22 2011 | GEVA | SYNAGEVA BIOPHARMA ... | Heberlig Chris | Vice President, Fin ... | Option Exercise | A | 23.00 | 15,000 | 345,000 | 15,000 | |
| Dec 21 2011 | GEVA | SYNAGEVA BIOPHARMA ... | Malley Thomas | Director | Option Exercise | A | 23.00 | 15,000 | 345,000 | 15,000 | |
| Dec 22 2011 | GEVA | SYNAGEVA BIOPHARMA ... | Goldberg Mark Alan | SVP, Product Dvp | Option Exercise | A | 23.00 | 15,000 | 345,000 | 15,000 | |
| Dec 21 2011 | GEVA | SYNAGEVA BIOPHARMA ... | BAKER FELIX | Director | Option Exercise | A | 23.00 | 15,000 | 345,000 | 15,000 | |
| Dec 21 2011 | GEVA | SYNAGEVA BIOPHARMA ... | Biggar Stephen R | Director | Option Exercise | A | 23.00 | 15,000 | 345,000 | 15,000 | |
| Dec 21 2011 | GEVA | SYNAGEVA BIOPHARMA ... | Samuels Robyn | Director | Option Exercise | A | 23.00 | 15,000 | 345,000 | 15,000 | |
| Dec 13 2011 | GEVA | SYNAGEVA BIOPHARMA ... | Malley Thomas | Director | Option Exercise | M | 0.95 | 1,976 | 1,877 | 2,199 | |
| Dec 13 2011 | GEVA | SYNAGEVA BIOPHARMA ... | Malley Thomas | Director | Option Exercise | M | 0.95 | 7,976 | 7,577 | 5,226 | |
| Dec 13 2011 | GEVA | SYNAGEVA BIOPHARMA ... | Malley Thomas | Director | Option Exercise | M | 3.52 | 1,186 | 4,175 | 51 | |
| Dec 13 2011 | GEVA | SYNAGEVA BIOPHARMA ... | Malley Thomas | Director | Option Exercise | M | 3.52 | 2,062 | 7,258 | 0 | |
| Dec 13 2011 | GEVA | SYNAGEVA BIOPHARMA ... | Malley Thomas | Director | Buy | M | 0.95 | 1,976 | 1,877 | 46,901 | 44.9 K to 46.9 K (+4.40 %) |
| Dec 13 2011 | GEVA | SYNAGEVA BIOPHARMA ... | Malley Thomas | Director | Buy | M | 0.95 | 7,976 | 7,577 | 44,925 | 36.9 K to 44.9 K (+21.59 %) |
| Dec 13 2011 | GEVA | SYNAGEVA BIOPHARMA ... | Malley Thomas | Director | Buy | M | 3.52 | 1,186 | 4,175 | 36,949 | 35.8 K to 36.9 K (+3.32 %) |
| Dec 13 2011 | GEVA | SYNAGEVA BIOPHARMA ... | Malley Thomas | Director | Buy | M | 3.52 | 2,062 | 7,258 | 35,763 | 33.7 K to 35.8 K (+6.12 %) |
| Dec 21 2011 | GEVA | SYNAGEVA BIOPHARMA ... | AKKARAJU SRINIVAS | Director | Option Exercise | A | 23.00 | 15,000 | 345,000 | 15,000 | |
| Nov 04 2011 | GEVA | SYNAGEVA BIOPHARMA ... | Baker Brothers Life Sciences C ... | Director | Grant | A | 0.00 | 3,253,761 | 0 | 4,000,451 | 746.7 K to 4 M (+435.76 %) |
| Nov 04 2011 | GEVA | SYNAGEVA BIOPHARMA ... | Baker Brothers Life Sciences C ... | Director | Grant | A | 0.00 | 251,971 | 0 | 746,690 | 494.7 K to 746.7 K (+50.93 %) |
| Nov 04 2011 | GEVA | SYNAGEVA BIOPHARMA ... | Baker Brothers Life Sciences C ... | Director | Grant | A | 0.00 | 244,194 | 0 | 494,719 | 250.5 K to 494.7 K (+97.47 %) |
| Nov 09 2011 | GEVA | SYNAGEVA BIOPHARMA ... | PERCEPTIVE ADVISORS LLC | 10% Owner | Sell | J | 0.00 | 2,340,000 | 0 | 0 | 2.3 M to 0 (-100.00 %) |
| Nov 04 2011 | GEVA | SYNAGEVA BIOPHARMA ... | BAKER FELIX | Director | Option Exercise | A | 2,350.00 | 1 | 2,350 | 1 | |
| Nov 04 2011 | GEVA | SYNAGEVA BIOPHARMA ... | BAKER FELIX | Director | Option Exercise | A | 2,350.00 | 1 | 2,350 | 1 | |
| Nov 04 2011 | GEVA | SYNAGEVA BIOPHARMA ... | BAKER FELIX | Director | Grant | A | 0.00 | 135,462 | 0 | 143,962 | 8.5 K to 144 K (+1,593.67 %) |
| Nov 04 2011 | GEVA | SYNAGEVA BIOPHARMA ... | BAKER JULIAN | 10% Owner | Grant | A | 0.00 | 135,462 | 0 | 144,082 | 8.6 K to 144.1 K (+1,571.48 %) |
| Nov 04 2011 | GEVA | SYNAGEVA BIOPHARMA ... | Baker Bros. Capital (GP), LLC | Director | Grant | A | 0.00 | 474 | 0 | 220,692 | 220.2 K to 220.7 K (+0.22 %) |
| Nov 04 2011 | GEVA | SYNAGEVA BIOPHARMA ... | Baker Bros. Capital (GP), LLC | Director | Grant | A | 0.00 | 76,484 | 0 | 220,218 | 143.7 K to 220.2 K (+53.21 %) |
| Nov 04 2011 | GEVA | SYNAGEVA BIOPHARMA ... | Baker Bros. Capital (GP), LLC | Director | Grant | A | 0.00 | 77,141 | 0 | 143,734 | 66.6 K to 143.7 K (+115.84 %) |
| Nov 04 2011 | GEVA | SYNAGEVA BIOPHARMA ... | Baker Bros. Capital (GP), LLC | Director | Grant | A | 0.00 | 5,292 | 0 | 66,593 | 61.3 K to 66.6 K (+8.63 %) |
| Nov 04 2011 | GEVA | SYNAGEVA BIOPHARMA ... | 14159 capital (GP), LLC | Director | Grant | A | 0.00 | 90,457 | 0 | 106,650 | 16.2 K to 106.7 K (+558.62 %) |
| Nov 04 2011 | GEVA | SYNAGEVA BIOPHARMA ... | 14159 capital (GP), LLC | Director | Grant | A | 0.00 | 8,185 | 0 | 16,193 | 8 K to 16.2 K (+102.21 %) |
| Nov 04 2011 | GEVA | SYNAGEVA BIOPHARMA ... | 14159 capital (GP), LLC | Director | Grant | A | 0.00 | 7,932 | 0 | 8,008 | 76 to 8 K (+10,436.84 %) |
| Nov 04 2011 | GEVA | SYNAGEVA BIOPHARMA ... | Baker Biotech Capital (GP), LL ... | Director | Grant | A | 0.00 | 1,046,755 | 0 | 1,548,489 | 501.7 K to 1.5 M (+208.63 %) |
| Nov 04 2011 | GEVA | SYNAGEVA BIOPHARMA ... | Baker Biotech Capital (GP), LL ... | Director | Grant | A | 0.00 | 127,527 | 0 | 501,734 | 374.2 K to 501.7 K (+34.08 %) |
| Nov 04 2011 | GEVA | SYNAGEVA BIOPHARMA ... | Baker Biotech Capital (GP), LL ... | Director | Grant | A | 0.00 | 123,591 | 0 | 374,207 | 250.6 K to 374.2 K (+49.31 %) |
| Nov 04 2011 | GEVA | SYNAGEVA BIOPHARMA ... | Baker / Tisch Capital (GP), LL ... | Director | Grant | A | 0.00 | 55,187 | 0 | 206,800 | 151.6 K to 206.8 K (+36.40 %) |
| Nov 04 2011 | GEVA | SYNAGEVA BIOPHARMA ... | Baker / Tisch Capital (GP), LL ... | Director | Grant | A | 0.00 | 53,754 | 0 | 151,613 | 97.9 K to 151.6 K (+54.93 %) |
| Nov 04 2011 | GEVA | SYNAGEVA BIOPHARMA ... | Baker / Tisch Capital (GP), LL ... | Director | Grant | A | 0.00 | 56,954 | 0 | 97,859 | 40.9 K to 97.9 K (+139.23 %) |
| Nov 04 2011 | GEVA | SYNAGEVA BIOPHARMA ... | Baker / Tisch Capital (GP), LL ... | Director | Grant | A | 0.00 | 8,821 | 0 | 40,905 | 32.1 K to 40.9 K (+27.49 %) |
| Aug 24 2011 | GEVA | SYNAGEVA BIOPHARMA ... | PERCEPTIVE ADVISORS LLC | 10% Owner | Sell | S | 2.01 | 6,600 | 13,266 | 2,333,400 | 2.3 M to 2.3 M (-0.28 %) |
| Aug 24 2011 | GEVA | SYNAGEVA BIOPHARMA ... | PERCEPTIVE ADVISORS LLC | 10% Owner | Sell | S | 2.11 | 1,500 | 3,165 | 2,340,000 | 2.3 M to 2.3 M (-0.06 %) |
| Aug 10 2011 | GEVA | SYNAGEVA BIOPHARMA ... | PERCEPTIVE ADVISORS LLC | 10% Owner | Buy | P | 2.18 | 10,000 | 21,800 | 0 | -10,000 to 0 (-100.00 %) |
| Aug 05 2011 | GEVA | SYNAGEVA BIOPHARMA ... | PERCEPTIVE ADVISORS LLC | 10% Owner | Buy | P | 2.23 | 30,000 | 66,900 | 0 | -30,000 to 0 (-100.00 %) |
| Aug 05 2011 | GEVA | SYNAGEVA BIOPHARMA ... | PERCEPTIVE ADVISORS LLC | 10% Owner | Buy | P | 2.25 | 10,000 | 22,500 | 0 | -10,000 to 0 (-100.00 %) |
| Aug 05 2011 | GEVA | SYNAGEVA BIOPHARMA ... | PERCEPTIVE ADVISORS LLC | 10% Owner | Buy | P | 2.19 | 30,000 | 65,700 | 0 | -30,000 to 0 (-100.00 %) |
| Jul 05 2011 | GEVA | SYNAGEVA BIOPHARMA ... | Baker Bros. Capital (GP), LLC | Director | Sell | J | 0.00 | 9,852 | 0 | 306,508 | 316.4 K to 306.5 K (-3.11 %) |
| Jul 05 2011 | GEVA | SYNAGEVA BIOPHARMA ... | Baker Brothers Life Sciences C ... | Director | Buy | J | 0.00 | 9,852 | 0 | 1,252,625 | 1.2 M to 1.3 M (+0.79 %) |
| Nov 24 2010 | GEVA | SYNAGEVA BIOPHARMA ... | Thomas James R | Chief Financial Off ... | Option Exercise | A | 2.51 | 100,000 | 251,000 | 135,000 | |
| Sep 30 2010 | GEVA | SYNAGEVA BIOPHARMA ... | Baker Brothers Life Sciences C ... | Director | Buy | P | 2.45 | 13,137 | 32,188 | 1,242,773 | 1.2 M to 1.2 M (+1.07 %) |
| Sep 30 2010 | GEVA | SYNAGEVA BIOPHARMA ... | Baker Brothers Life Sciences C ... | Director | Buy | P | 2.45 | 779 | 1,912 | 1,229,636 | 1.2 M to 1.2 M (+0.06 %) |
| Sep 30 2010 | GEVA | SYNAGEVA BIOPHARMA ... | 14159 capital (GP), LLC | Director | Buy | P | 2.45 | 363 | 889 | 384 | 21 to 384 (+1,728.57 %) |
| Sep 30 2010 | GEVA | SYNAGEVA BIOPHARMA ... | 14159 capital (GP), LLC | Director | Buy | P | 2.45 | 21 | 52 | 21 | 0 to 21 |
| Sep 24 2010 | GEVA | SYNAGEVA BIOPHARMA ... | BAKER JULIAN | Director | Option Exercise | A | 2.27 | 15,000 | 34,050 | 15,000 | |
| Sep 24 2010 | GEVA | SYNAGEVA BIOPHARMA ... | BAKER FELIX | Director | Option Exercise | A | 2.27 | 15,000 | 34,050 | 15,000 | |
| Sep 24 2010 | GEVA | SYNAGEVA BIOPHARMA ... | Thomas James R | Director | Option Exercise | A | 2.27 | 15,000 | 34,050 | 15,000 | |
| Sep 24 2010 | GEVA | SYNAGEVA BIOPHARMA ... | Quart Barry D | Director | Option Exercise | A | 2.27 | 15,000 | 34,050 | 15,000 | |
| Sep 24 2010 | GEVA | SYNAGEVA BIOPHARMA ... | DAVIS STEPHEN | Director | Option Exercise | A | 2.27 | 15,000 | 34,050 | 15,000 | |
| Sep 24 2010 | GEVA | SYNAGEVA BIOPHARMA ... | MATTINGLY MARTIN A | Chief Executive Off ... | Option Exercise | A | 2.27 | 89,088 | 202,230 | 89,088 | |
| Sep 24 2010 | GEVA | SYNAGEVA BIOPHARMA ... | Graham Andrew L | Chief Financial Off ... | Option Exercise | A | 2.27 | 44,544 | 101,115 | 44,544 | |
| Sep 24 2010 | GEVA | SYNAGEVA BIOPHARMA ... | Alrutz Michael A | General Counsel | Option Exercise | A | 2.27 | 44,544 | 101,115 | 44,544 | |
| Oct 13 2009 | GEVA | SYNAGEVA BIOPHARMA ... | BRIDGER MANAGEMENT LLC | 10% Owner | Sell | S | 3.53 | 2,136,858 | 7,550,588 | 373,223 | 2.5 M to 373.2 K (-85.13 %) |
| Aug 14 2009 | GEVA | SYNAGEVA BIOPHARMA ... | Thomas James R | Director | Option Exercise | A | 2.33 | 20,000 | 46,600 | 20,000 | |
| Jul 23 2009 | GEVA | SYNAGEVA BIOPHARMA ... | HealthCor Management, L.P. | Director | Option Exercise | A | 2.02 | 20,000 | 40,400 | 20,000 | |
| Jul 23 2009 | GEVA | SYNAGEVA BIOPHARMA ... | HealthCor Management, L.P. | Director | Option Exercise | A | 2.02 | 20,000 | 40,400 | 20,000 | |
| Jul 22 2009 | GEVA | SYNAGEVA BIOPHARMA ... | Graham Andrew L | Chief Financial Off ... | Option Exercise | A | 2.02 | 44,544 | 89,979 | 44,544 | |
| Jul 22 2009 | GEVA | SYNAGEVA BIOPHARMA ... | Alrutz Michael A | General Counsel | Option Exercise | A | 2.02 | 44,544 | 89,979 | 44,544 | |
| Jul 22 2009 | GEVA | SYNAGEVA BIOPHARMA ... | MATTINGLY MARTIN A | Chief Executive Off ... | Option Exercise | A | 2.02 | 89,088 | 179,958 | 89,088 | |
| Jul 22 2009 | GEVA | SYNAGEVA BIOPHARMA ... | BAKER FELIX | Director | Option Exercise | A | 2.02 | 13,750 | 27,775 | 13,750 | |
| Jul 22 2009 | GEVA | SYNAGEVA BIOPHARMA ... | BAKER JULIAN | Director | Option Exercise | A | 2.02 | 12,500 | 25,250 | 12,500 | |
| Jul 22 2009 | GEVA | SYNAGEVA BIOPHARMA ... | DAVIS STEPHEN | Director | Option Exercise | A | 2.02 | 15,000 | 30,300 | 15,000 | |
| Jul 22 2009 | GEVA | SYNAGEVA BIOPHARMA ... | Quart Barry D | Director | Option Exercise | A | 2.02 | 13,750 | 27,775 | 13,750 | |
| Jan 29 2009 | GEVA | SYNAGEVA BIOPHARMA ... | BAKER JULIAN | Director | Option Exercise | A | 4.12 | 12,500 | 51,500 | 12,500 | |
| Jan 29 2009 | GEVA | SYNAGEVA BIOPHARMA ... | BAKER JULIAN | Director | Option Exercise | D | 5.03 | 12,500 | 62,875 | 0 | |
| Jan 29 2009 | GEVA | SYNAGEVA BIOPHARMA ... | BAKER JULIAN | Director | Option Exercise | A | 5.00 | 13,750 | 68,750 | 13,750 | |
| Jan 29 2009 | GEVA | SYNAGEVA BIOPHARMA ... | BAKER JULIAN | Director | Option Exercise | D | 5.91 | 13,750 | 81,263 | 0 | |
| Jan 29 2009 | GEVA | SYNAGEVA BIOPHARMA ... | BAKER JULIAN | Director | Option Exercise | A | 6.74 | 11,250 | 75,825 | 11,250 | |
| Jan 29 2009 | GEVA | SYNAGEVA BIOPHARMA ... | BAKER JULIAN | Director | Option Exercise | D | 7.65 | 11,250 | 86,063 | 0 | |
| Jan 29 2009 | GEVA | SYNAGEVA BIOPHARMA ... | BAKER JULIAN | Director | Option Exercise | A | 10.57 | 11,250 | 118,913 | 11,250 | |
| Jan 29 2009 | GEVA | SYNAGEVA BIOPHARMA ... | BAKER JULIAN | Director | Option Exercise | D | 11.48 | 11,250 | 129,150 | 0 | |
| Jan 29 2009 | GEVA | SYNAGEVA BIOPHARMA ... | BAKER JULIAN | Director | Option Exercise | A | 12.09 | 11,250 | 136,013 | 11,250 | |
| Jan 29 2009 | GEVA | SYNAGEVA BIOPHARMA ... | BAKER JULIAN | Director | Option Exercise | D | 13.00 | 11,250 | 146,250 | 0 | |
| Jan 29 2009 | GEVA | SYNAGEVA BIOPHARMA ... | BAKER JULIAN | Director | Option Exercise | A | 13.02 | 20,000 | 260,400 | 20,000 | |
| Jan 29 2009 | GEVA | SYNAGEVA BIOPHARMA ... | BAKER JULIAN | Director | Option Exercise | D | 13.93 | 20,000 | 278,600 | 0 | |
| Jan 29 2009 | GEVA | SYNAGEVA BIOPHARMA ... | BAKER FELIX | Director | Option Exercise | A | 4.12 | 13,750 | 56,650 | 13,750 | |
| Jan 29 2009 | GEVA | SYNAGEVA BIOPHARMA ... | BAKER FELIX | Director | Option Exercise | D | 5.03 | 13,750 | 69,163 | 0 | |
| Jan 29 2009 | GEVA | SYNAGEVA BIOPHARMA ... | BAKER FELIX | Director | Option Exercise | A | 5.00 | 13,750 | 68,750 | 13,750 | |
| Jan 29 2009 | GEVA | SYNAGEVA BIOPHARMA ... | BAKER FELIX | Director | Option Exercise | D | 5.91 | 13,750 | 81,263 | 0 | |
| Jan 29 2009 | GEVA | SYNAGEVA BIOPHARMA ... | BAKER FELIX | Director | Option Exercise | A | 6.74 | 11,250 | 75,825 | 11,250 | |
| Jan 29 2009 | GEVA | SYNAGEVA BIOPHARMA ... | BAKER FELIX | Director | Option Exercise | D | 7.65 | 11,250 | 86,063 | 0 | |
| Jan 29 2009 | GEVA | SYNAGEVA BIOPHARMA ... | BAKER FELIX | Director | Option Exercise | A | 10.57 | 11,250 | 118,913 | 11,250 | |
| Jan 29 2009 | GEVA | SYNAGEVA BIOPHARMA ... | BAKER FELIX | Director | Option Exercise | D | 11.48 | 11,250 | 129,150 | 0 | |
| Jan 29 2009 | GEVA | SYNAGEVA BIOPHARMA ... | BAKER FELIX | Director | Option Exercise | A | 12.09 | 11,250 | 136,013 | 11,250 | |
| Jan 29 2009 | GEVA | SYNAGEVA BIOPHARMA ... | BAKER FELIX | Director | Option Exercise | D | 13.00 | 11,250 | 146,250 | 0 | |
| Jan 29 2009 | GEVA | SYNAGEVA BIOPHARMA ... | BAKER FELIX | Director | Option Exercise | A | 13.02 | 20,000 | 260,400 | 20,000 | |
| Jan 29 2009 | GEVA | SYNAGEVA BIOPHARMA ... | BAKER FELIX | Director | Option Exercise | D | 13.93 | 20,000 | 278,600 | 0 | |
| Jan 29 2009 | GEVA | SYNAGEVA BIOPHARMA ... | Graham Andrew L | Chief Financial Off ... | Option Exercise | A | 6.53 | 2,813 | 18,369 | 2,813 | |
| Jan 29 2009 | GEVA | SYNAGEVA BIOPHARMA ... | Graham Andrew L | Chief Financial Off ... | Option Exercise | D | 7.44 | 2,813 | 20,929 | 0 |